Hologic—a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products—and laser manufacturer Cynosure have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, for a total cost of approximately $1.65 billion. The boards of directors of both companies have approved the transaction unanimously.
“Acquiring Cynosure will accelerate our transformation into a higher-growth company by leveraging our core women’s health expertise and OB/GYN channel leadership into an adjacent, cash-pay segment that is expanding at a low double-digit rate,” said Steve MacMillan, Hologic’s chairman, president and CEO. “We had identified medical aesthetics as an attractive and complementary growth opportunity through our strategic planning process, and are pleased to have agreed to acquire Cynosure, the best-in-class company in the space. Together, we can strengthen our shared focus on innovation, market-leading products with demonstrated clinical benefits, and strong customer relationships.”